 BURNABY, British Columbia, Oct. 08, 2021 GLOBE NEWSWIRE -- Xenon Pharmaceuticals Inc. Nasdaq:XENE, a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 10,000,000 common shares, which includes 1,525,423 shares sold upon the full exercise of the underwriters option to purchase additional shares, and pre-funded warrants to purchase 1,694,915 common shares. The common shares were offered at a public offering price of 29.50 per common share and the pre-funded warrants were offered at a price of 29.4999 per pre-funded warrant, with each pre-funded warrant having an exercise price of 0.0001. The aggregate gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, were approximately 345.0 million. 